- Home
- JELD vs AARD Comparison
JELD vs AARD Comparison
Compare JELD & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JELD | AARD |
|---|---|---|
| Founded | 1960 | 2017 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.9M | 85.7M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | JELD | AARD |
|---|---|---|
| Price | $1.14 | $3.96 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $3.43 | ★ $15.29 |
| AVG Volume (30 Days) | ★ 2.1M | 242.6K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $3.35 |
| 52 Week High | $6.98 | $17.94 |
Technical Indicators
Market Signals| Indicator | JELD | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 29.96 |
| Support Level | N/A | $3.35 |
| Resistance Level | $2.06 | $4.39 |
| Average True Range (ATR) | 0.11 | 0.29 |
| MACD | 0.03 | 0.28 |
| Stochastic Oscillator | 54.55 | 57.69 |
Price Performance
Historical ComparisonAbout JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.